Noblesville, IN, USA, August 14, 2007 – Verdure Sciences announced today that POMELLA® Extract, the clinically researched natural spectrum pomegranate extract standardized to punicalagins, has been granted approval for use in complementary medicine products in Australia by the Therapeutic Goods Administration (TGA).
The approval arrives during increasing consumer awareness of pomegranate’s health benefits, particularly pomegranate extracts.
A substantial amount of published research supports the use of natural-spectrum pomegranate fruit extracts for cardiovascular and cellular health—as well as several other targeted health issues—with none of the sugar, calories, or polyphenol inconsistency of pomegranate juice.
“With all the recent interest in the tangible health benefits pomegranate can offer, we are excited that POMELLA® Extract is now TGA approved and available to Australian and New Zealand customers through our close relationship with Pathway International,” said Blake Ebersole, Technical Director of Verdure Sciences.
About POMELLA® Extract:
POMELLA® Extract is made from the whole pomegranate’s natural polyphenolic spectrum, including ellagitannin and punicalagins content, and is supported by complete efficacy and safety profiles. POMELLA® Extract shows the potential to significantly increase antioxidant capacity of human plasma after consumption in published research. POMELLA® Extract, derived from the whole pomegranate fruit, is manufactured at Verdure Sciences’ ISO-9000:2001, HACCP facility; is Kosher-certified, Halal-certified, and GMO-free; and made from pomegranate fruits grown on Verdure Sciences’ vertically integrated pesticide-free farms. More info can be found at www.pomextract.com.
About Pathway International Pty Ltd.
Pathway International is the exclusive distributor in Australia and New Zealand for leading suppliers of high quality and innovative ingredients that add value to the health care and nutrition industries.
Contact: Blake Ebersole